Cargando…

Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer

Purpose: The objective of this study was to analyze the safety and efficacy of definitive chemoradiotherapy and salvage chemotherapy in pancreatic cancer (PC) patients with isolated locoregional recurrence after radical resection and assess the factors associated with tumor response. Patients and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wei, Jiang, Rui, Liang, Fei, Yu, Genhua, Long, Jiang, Zhao, Jiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549434/
https://www.ncbi.nlm.nih.gov/pubmed/31213918
http://dx.doi.org/10.2147/CMAR.S202543
_version_ 1783424008198291456
author Shi, Wei
Jiang, Rui
Liang, Fei
Yu, Genhua
Long, Jiang
Zhao, Jiandong
author_facet Shi, Wei
Jiang, Rui
Liang, Fei
Yu, Genhua
Long, Jiang
Zhao, Jiandong
author_sort Shi, Wei
collection PubMed
description Purpose: The objective of this study was to analyze the safety and efficacy of definitive chemoradiotherapy and salvage chemotherapy in pancreatic cancer (PC) patients with isolated locoregional recurrence after radical resection and assess the factors associated with tumor response. Patients and methods: A retrospective study of isolated locoregional recurrent PC patients who were treated with definitive chemoradiotherapy and salvage chemotherapy at our institution between 2012 and 2017 was conducted. Medium dose of 56.0 Gy (range: 54.0 Gy - 60.2 Gy) in 1.8 Gy to 2.15 Gy daily fractions was prescribed to the PTV-G and 50.4 Gy was prescribed to the PTV-C. Patients received chemotherapy before, at the same time with or after radiotherapy. The overall survival (OS) and freedom from locoregional progression (FFLP) rates were estimated by the Kaplan–Meier method, and the log-rank test was performed to compare survival curves. The Cox regression was used to identify factors affecting response to treatment and survival. Results: Thirty-one patients were included. The median interval from the resection of primary PC to the diagnosis of the locoregional recurrence (DFI) was 7.4 months (range 0.2–44.6). Within a median follow-up from the start of radiotherapy (RT) of 31.7 months (95% CI: 20.0–43.5 months), the medium OS and FFLP rates from the start of RT were 23.6 and 12.0 months, respectively. DFI >6 months was shown to be a significant factor associated with favorable OS. Acute and late toxicity of grade 3 occurred in 3 patients (9.7%) and 1 patient (3.2%) respectively. No grade 4 toxicity or higher occurred. Conclusions: This single-institution retrospective analysis identified definitive chemoradiotherapy and salvage chemotherapy to be a feasible and tolerable treatment strategy for patients with isolated locoregional recurrence after radical resection of primary PC.
format Online
Article
Text
id pubmed-6549434
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65494342019-06-18 Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer Shi, Wei Jiang, Rui Liang, Fei Yu, Genhua Long, Jiang Zhao, Jiandong Cancer Manag Res Original Research Purpose: The objective of this study was to analyze the safety and efficacy of definitive chemoradiotherapy and salvage chemotherapy in pancreatic cancer (PC) patients with isolated locoregional recurrence after radical resection and assess the factors associated with tumor response. Patients and methods: A retrospective study of isolated locoregional recurrent PC patients who were treated with definitive chemoradiotherapy and salvage chemotherapy at our institution between 2012 and 2017 was conducted. Medium dose of 56.0 Gy (range: 54.0 Gy - 60.2 Gy) in 1.8 Gy to 2.15 Gy daily fractions was prescribed to the PTV-G and 50.4 Gy was prescribed to the PTV-C. Patients received chemotherapy before, at the same time with or after radiotherapy. The overall survival (OS) and freedom from locoregional progression (FFLP) rates were estimated by the Kaplan–Meier method, and the log-rank test was performed to compare survival curves. The Cox regression was used to identify factors affecting response to treatment and survival. Results: Thirty-one patients were included. The median interval from the resection of primary PC to the diagnosis of the locoregional recurrence (DFI) was 7.4 months (range 0.2–44.6). Within a median follow-up from the start of radiotherapy (RT) of 31.7 months (95% CI: 20.0–43.5 months), the medium OS and FFLP rates from the start of RT were 23.6 and 12.0 months, respectively. DFI >6 months was shown to be a significant factor associated with favorable OS. Acute and late toxicity of grade 3 occurred in 3 patients (9.7%) and 1 patient (3.2%) respectively. No grade 4 toxicity or higher occurred. Conclusions: This single-institution retrospective analysis identified definitive chemoradiotherapy and salvage chemotherapy to be a feasible and tolerable treatment strategy for patients with isolated locoregional recurrence after radical resection of primary PC. Dove 2019-05-31 /pmc/articles/PMC6549434/ /pubmed/31213918 http://dx.doi.org/10.2147/CMAR.S202543 Text en © 2019 Shi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shi, Wei
Jiang, Rui
Liang, Fei
Yu, Genhua
Long, Jiang
Zhao, Jiandong
Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title_full Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title_fullStr Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title_full_unstemmed Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title_short Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
title_sort definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549434/
https://www.ncbi.nlm.nih.gov/pubmed/31213918
http://dx.doi.org/10.2147/CMAR.S202543
work_keys_str_mv AT shiwei definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer
AT jiangrui definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer
AT liangfei definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer
AT yugenhua definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer
AT longjiang definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer
AT zhaojiandong definitivechemoradiotherapyandsalvagechemotherapyforpatientswithisolatedlocoregionalrecurrenceafterradicalresectionofprimarypancreaticcancer